Kindred Biosciences, Inc. (KIN) EPS Estimated At $-0.40

October 13, 2018 - By Clifton Ray

Kindred Biosciences, Inc. (NASDAQ:KIN) LogoInvestors sentiment increased to 2 in Q2 2018. Its up 1.22, from 0.78 in 2018Q1. It improved, as 3 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 15 funds opened positions while 23 raised stakes. 19.86 million shares or 17.97% more from 16.83 million shares in 2018Q1 were reported.
Renaissance Technology Ltd Limited Liability Company reported 695,200 shares stake. Northern Corp stated it has 288,387 shares. Pdt Ptnrs holds 22,199 shares or 0.01% of its portfolio. Ubs Oconnor Limited Liability invested in 100,000 shares. Evanson Asset Mgmt Limited Com holds 16,545 shares. Paloma Management Communication accumulated 0% or 11,200 shares. Sit Inc reported 0.02% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). Morgan Stanley holds 0.01% or 2.16 million shares. Wells Fargo Com Mn owns 321,906 shares. Ariel Investments Limited Liability Com reported 2.22 million shares or 0.27% of all its holdings. Ameritas Inv Prtnrs holds 1,848 shares or 0% of its portfolio. Granahan Inv Mngmt Ma holds 0.2% or 318,741 shares. Park West Asset Ltd Liability stated it has 2.38% in Kindred Biosciences, Inc. (NASDAQ:KIN). Moreover, General has 0.58% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 594,878 shares. Goldman Sachs stated it has 0% in Kindred Biosciences, Inc. (NASDAQ:KIN).

Since May 1, 2018, it had 1 insider buy, and 7 insider sales for $6.24 million activity. Shares for $8.03M were bought by Park West Asset Management LLC on Wednesday, June 20.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.40 EPS on November, 6.They anticipate $0.11 EPS change or 37.93 % from last quarter’s $-0.29 EPS. After having $-0.39 EPS previously, Kindred Biosciences, Inc.’s analysts see 2.56 % EPS growth. The stock increased 2.94% or $0.34 during the last trading session, reaching $11.9. About 383,832 shares traded or 88.86% up from the average. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 85.33% since October 14, 2017 and is uptrending. It has outperformed by 69.71% the S&P500.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 5 analysts covering Kindred Biosciences (NASDAQ:KIN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Kindred Biosciences had 6 analyst reports since May 9, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, June 26. The firm has “Buy” rating given on Tuesday, August 7 by FBR Capital. H.C. Wainwright maintained Kindred Biosciences, Inc. (NASDAQ:KIN) on Wednesday, May 9 with “Buy” rating. The firm earned “Neutral” rating on Tuesday, August 7 by Ladenburg Thalmann.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $402.22 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Another recent and important Kindred Biosciences, Inc. (NASDAQ:KIN) news was published by which published an article titled: “Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare …” on September 17, 2018.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News